Competing interests
M.C.S., J.A.F., B.S., A.V., R.L., C.F., C.R.T., K.T., A.K., S.C., C.S., K.X., P.J., A.C., H.E.S., V.C., W.L., J.T.J., M.R.Y., A.S., S.S., M.H., O.O., H.G., C.C., S.L., N.T., E.H.S., C.K., R.P., G.O. and J.S.M. declare no competing interests. J.K.L. holds equity in Standard BioTools and is on the scientific advisory board for MBQ Pharma. N.H. holds equity in and advises Repertoire Immune Medicines, CytoReason and Danger Bio/Related Sciences, owns equity and has licensed patents to BioNtech, and receives research funding from Bristol Myers Squibb, Moderna, ResolveM/JJDC, Takeda and Calico Life Sciences. U.A.M. declares participation in scientific advisory boards: NextCure, AbbVie, Immunogen, Profound Bio, Eisai, the Ovarian Cancer Research Alliance, Tango Therapeutics, Novartis, GSK, Daiichi Sankyo, DayOne Bio and Whitehawk Therapeutics; U.A.M. also reports participation in a data safety-monitoring board: Mural Oncology, Macrogenics, Daiichi Sankyo, AstraZeneca and Symphogen, all unrelated to this work. V.A.A. is a co-inventor of the MAESTRO MRD test, which has been licensed to Exact Sciences and receives research funding from Exact Sciences, which was not involved in this study. V.A.A. is also a co-founder and advisor to Amplifyer Bio. G.G. receives research funds from IBM, Pharmacyclics/AbbVie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite, AstraZeneca and Novartis and is also an inventor on patent applications filed by the Broad Institute, including those related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye, MinimuMM-seq, DLBclass, HapASeg, Tonly2, MSIDetect, TuFEst and ABSOLUTE2. A full list of G.G.’s publicly available patent applications can be requested from the Broad’s legal team at patents@broadinstitute.org. G.G is a founder, consultant, and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in Predicta Biosciences; and a consultant and holds privately held equity in Antares Therapeutics. D.B.K. owns equity in Affimed N.V., Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceuticals, Celldex Therapeutics, Editas Medicine, Immunitybio, Lexicon Pharmaceuticals, Moderna, PDS Biotechnology, Prime Medicine, Sana Biotechnologies and Viking Therapeutics. D.B.K. is a scientific advisor for Immunitrack, a wholly owned subsidiary of Eli Lilly and Company and Breakbio. P.A.O. has received research funding from and/or has advised Agenus, Arcturus, Amgen, Armo BioSciences, Array, AstraZeneca/MedImmune, Bristol-Meyers Squibb, Celldex, CytomX, Evaxion, Immunetune, Imunon, LGChem, Merck, Neon Therapeutics (now BioNTechUS), Novartis, Pharmajet, Phio, Pfizer, Oncorus, Roche/Genentech, Servier and Xencor. P.A.K. has received grants or contracts from Novartis, AstraZeneca, Pfizer, Eli Lilly, Bayer, Merck, GlaxoSmithKline, Tesaro and Merck KGaA and has received consulting fees for serving on advisory boards from AstraZeneca, Bayer, GlaxoSmithKline, Alkermes, Kadmon, Bristol Myers Squibb, IMV, Repare, Artios, Mersana, Novartis, Cardiff Oncology, Schrodinger, Mural Oncology, Scorpion and Nimbus. C.J.W. is an equity holder of BioNtech and is a scientific advisory board member of Repertoire, Aethon Therapeutics, Nature’s Toolbox and Adventris.
